The Trump administration has taken a step to partially reschedule cannabis by moving certain products from Schedule I to Schedule III, as announced by Acting Attorney General Todd Blanche. This change allows state medical cannabis products and prospective FDA-approved cannabis products to be recognized as legitimate medicine. However, experts like Cat Packer from the Drug Policy Alliance caution that this is a limited rescheduling and does not affect existing FDA-approved cannabis pharmaceuticals. The order has raised concerns about its implementation, particularly regarding the treatment of medical cannabis patients and the potential for discrimination in housing and employment. Additionally, the focus on medical cannabis may disproportionately benefit white entrepreneurs while excluding Black and Latino cannabis business owners. The administration's move has been viewed as politically motivated, particularly with upcoming midterm elections. A new administrative hearing by the Drug Enforcement Administration (DEA) regarding cannabis rescheduling is set for June 29, but full rescheduling remains uncertain, according to Packer.